New class of drugs for treatment type 2 diabetes mellitus (T2DM) are sodium-glucose cotransporter 2 (SGLT2) inhibitors. These drug are an antihyperglycaemic agents with an insulin-independent mode of action. One of the SGLT2 inhibitors class that used in Ukraine for treatment patients with T2DM is a Dapagliflozin. We try to summarize current evidence from different clinical trials that assess the clinical efficacy and safety of dapagliflozin.